Raised blood pressure remains the leading modifiable risk factor for cardiovascular disease and premature mortality worldwide ...
A bi-polar hormone that can contribute to strokes and minimize their damage is emerging as a therapeutic target in the battle against these brain attacks, researchers say. "It costs about $56 billion ...
– Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most ...
Purpose: The clinical benefits, adverse effects, pharmacokinetics, and recommendations for the appropriate use of the aldosterone antagonists spironolactone and eplerenone in patients with heart ...
Please provide your email address to receive an email when new articles are posted on . BI 690517 dose-dependently reduced urine albumin-to-creatine ratio, showing a potential albuminuria reduction.
Higher serum aldosterone levels among patients with chronic kidney disease (CKD) are independently associated with an increased risk for CKD progression and end-stage kidney disease (ESKD) regardless ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results